Treating sleep apnoea aids glaucoma control

Article

Severe obstructive sleep apnoea (OSA) is an important risk factor for developing glaucoma and must be treated in those who have it to improve control of the eye disease, according to new research.

Severe obstructive sleep apnoea (OSA) is an important risk factor for developing glaucoma and must be treated in those who have it to improve control of the eye disease, according to new research published in Eye.

Researchers in Qatar assessed for glaucoma in 39 adults who had been diagnosed with moderate or severe OSA. They classified the severity of OSA as mild, moderate, or severe using American Association of Sleep Medicine (AASM) criteria and the apnoea hypopnoea index. All study participants underwent serial visual field tests, optical coherence tomography with fundus photography, and pachymetry before the study began, and they were followed in an ophthalmology outpatient clinic and a sleep clinic for 3 years.

The investigators discovered that 8 (20.5%) of the study participants who had OSA also had glaucoma; 6 (75%) of them had normal-tension glaucoma (NTG), and 2 (25%) had the high-tension version. Among the 27 participants in whom OSA was classified as severe, the eye disease was present in 7 (25.9%), and among 12 patients with moderate OSA, the eye disease was present in 1 (8.3%).

During follow-up, two participants in whom glaucoma originally had not been diagnosed were reclassified as having NTG. Also, the condition of two participants who had glaucoma deteriorated. A higher prevalence of glaucoma existed in those with severe OSA than in those with moderate OSA, although the difference was not statistically significant.

For more detailed information visit the journal's website.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.